Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CVM > SEC Filings for CVM > Form 8-K on 10-Oct-2013All Recent SEC Filings

Show all filings for CEL SCI CORP

Form 8-K for CEL SCI CORP


Entry into a Material Definitive Agreement, Other Events, Financial Statements and E

Item 1.01 Entry Into a Material Definitive Agreement.

On October 8, 2013, CEL-SCI Corporation (the "Company"), Chardan Capital Markets, LLC and Laidlaw & Company (UK) Ltd (the "Underwriters"), entered into an underwriting agreement (the "Underwriting Agreement") to issue and sell 17,826,087 shares of the Company's common stock, as well as warrants to purchase an additional 17,826,087 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one share for the combined purchase price of $1.00, minus underwriting discounts and commissions. The Company has granted the Underwriters an option to purchase up to 2,673,913 additional shares of common stock and/or warrants to purchase up to 2,673,913 additional shares of common stock, for the combined purchase price of $1.00 for one share and one warrant, minus underwriting discounts and commissions, or the separate purchase prices per share or warrant, as applicable, set forth in the Underwriting Agreement. The option is exercisable, in whole or in part, for a period of 45 days after October 8, 2013.

The net proceeds are expected to be approximately $16,300,000, after deducting the underwriting discounts and commissions and estimated expenses payable by the Company, and without exercise of the Underwriters' over-allotment option.

The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, and customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. These representations, warranties and covenants are not factual information to investors about the Company.

The offering is being made pursuant to the Registration Statement and Prospectus Supplement discussed below under Item 8.01. The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Hart & Hart, LLC relating to the legality of the issuance and sale of the shares and warrants in the offering is attached as Exhibit 5 hereto.

On October 7, 2013, the Company issued a press release announcing that it had commenced the offering. A copy of this press release is attached hereto as Exhibit 99.1. On October 8, 2013, the Company issued a press release announcing that it had priced the offering. A copy of the press release is attached hereto as Exhibit 99.2.

Item 8.01 Other Events.

On October 9, 2013, the Company filed with the Securities Exchange Commission (the "Commission") a prospectus supplement (the "Prospectus Supplement") to the prospectus (the "Prospectus") included as part of the Company's registration statement on Form S-3 declared effective by the

Commission on October 5, 2012 (File No. 333-184094) (the "Registration Statement"), pursuant to which the Company will sell, in an underwritten offering, 17,826,087 shares of the Company's common stock, as well as warrants to purchase an additional 17,826,087 shares of common stock.

Prospective investors should read the Registration Statement, the Prospectus dated October 4, 2013 which was filed with the Commission on October 7, 2013 and the Prospectus Supplement, and all documents incorporated by reference by the foregoing.

This transaction mentioned in Item 1.01 of this report caused the following adjustment to the securities sold in CEL-SCI's August 2008 financing:

o The Series N warrants now allow the holders to purchase up to 1,189,961shares of CEL-SCI's common stock at a price of $0.91 per share; and

o an additional 764,602 shares of common stock were issued to one investor which participated in the August 2008 financing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit     Description

1.1         Underwriting Agreement dated October 8, 2013.

5           Opinion of Hart & Hart, LLC

23          Consent of Hart & Hart, LLC

99.1        Press Release dated October 7, 2013.

99.2        Press Release dated October 8, 2013.

  Add CVM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CVM - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.